Protara Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Protara Therapeutics, Inc. (TARA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$2.50 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-20.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2020-03-20
- Protara Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-12-31 was -$1.03M, a 289.71% decline year-over-year.
- Protara Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-09-30 was -$442.00K, a 245.87% decline year-over-year.
- Protara Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-06-30 was -$1.18M.
- Protara Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-03-31 was $155.00K.
- Protara Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2019 was -$2.50M.
- Protara Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2018 was -$6.16M, a 248.09% decline from fiscal 2017.
- Protara Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2017 was $4.16M, a 287.79% increase from fiscal 2016.
- Protara Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2016 was $1.07M, a 14.71% decline from fiscal 2015.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | -$1.47M derived: sum of 2 quarters · filed 2020-03-20 | -$2.65M derived: sum of 3 quarters · filed 2020-03-20 | -$2.50M 10-K · filed 2020-03-20 |
| 2019-09-30 | -$442.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$1.62M derived: sum of 2 quarters · filed 2019-10-31 | -$1.47M 10-Q · filed 2019-10-31 | -$921.00K derived: sum of 4 quarters · filed 2020-03-20 |
| 2019-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$1.02M 10-Q · filed 2019-08-07 | -$479.00K derived: sum of 3 quarters · filed 2020-03-20 | -$176.00K derived: sum of 4 quarters · filed 2020-03-20 |
| 2019-03-31 | $155.00K 10-Q · filed 2019-05-08 | $699.00K derived: sum of 2 quarters · filed 2020-03-20 | $1.00M derived: sum of 3 quarters · filed 2020-03-20 | -$5.79M derived: sum of 4 quarters · filed 2020-03-20 |
| 2018-12-31 | $544.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $847.00K derived: sum of 2 quarters · filed 2020-03-20 | -$5.94M derived: sum of 3 quarters · filed 2020-03-20 | -$6.16M 10-K · filed 2020-03-20 |
| 2018-09-30 | $303.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$6.49M derived: sum of 2 quarters · filed 2019-10-31 | -$6.71M 10-Q · filed 2019-10-31 | -$6.56M derived: sum of 4 quarters · filed 2019-10-31 |
| 2018-06-30 | -$6.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$7.01M 10-Q · filed 2019-08-07 | -$6.86M derived: sum of 3 quarters · filed 2019-08-07 | -$1.91M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | -$220.00K 10-Q · filed 2019-05-08 | -$74.00K derived: sum of 2 quarters · filed 2019-05-08 | $4.88M derived: sum of 3 quarters · filed 2019-05-08 | $6.00M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $146.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $5.10M derived: sum of 2 quarters · filed 2019-03-13 | $6.22M derived: sum of 3 quarters · filed 2019-03-13 | $4.16M 10-K · filed 2019-03-13 |
| 2017-09-30 | $4.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $6.07M derived: sum of 2 quarters · filed 2018-11-07 | $4.01M 10-Q · filed 2018-11-07 | $4.22M derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$942.00K 10-Q · filed 2018-08-07 | -$738.00K derived: sum of 3 quarters · filed 2019-03-13 | -$599.00K derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-03-31 | -$2.06M 10-Q · filed 2018-05-09 | -$1.85M derived: sum of 2 quarters · filed 2019-03-13 | -$1.71M derived: sum of 3 quarters · filed 2019-03-13 | -$616.00K derived: sum of 4 quarters · filed 2019-03-13 |
| 2016-12-31 | $204.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $343.00K derived: sum of 2 quarters · filed 2019-03-13 | $1.44M derived: sum of 3 quarters · filed 2019-03-13 | $1.07M 10-K · filed 2019-03-13 |
| 2016-09-30 | $139.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $1.24M derived: sum of 2 quarters · filed 2017-11-07 | $869.00K 10-Q · filed 2017-11-07 | $1.64M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $730.00K 10-Q · filed 2017-08-07 | $1.50M derived: sum of 3 quarters · filed 2018-03-14 | $1.62M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | -$367.00K 10-Q · filed 2017-05-10 | $403.00K derived: sum of 2 quarters · filed 2018-03-14 | $525.00K derived: sum of 3 quarters · filed 2018-03-14 | $595.00K derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $770.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $892.00K derived: sum of 2 quarters · filed 2018-03-14 | $962.00K derived: sum of 3 quarters · filed 2018-03-14 | $1.26M 10-K · filed 2018-03-14 |
| 2015-09-30 | $122.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $192.00K derived: sum of 2 quarters · filed 2016-11-07 | $488.00K 10-Q · filed 2016-11-07 | $168.00K derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $366.00K 10-Q · filed 2016-08-08 | $46.00K derived: sum of 3 quarters · filed 2017-03-16 | -$296.00K derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | $296.00K 10-Q · filed 2016-05-09 | -$24.00K derived: sum of 2 quarters · filed 2017-03-16 | -$366.00K derived: sum of 3 quarters · filed 2017-03-16 | $662.00K derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | -$320.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$662.00K derived: sum of 2 quarters · filed 2017-03-16 | $366.00K derived: sum of 3 quarters · filed 2017-03-16 | $955.00K 10-K · filed 2017-03-16 |
| 2014-09-30 | -$342.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $686.00K derived: sum of 2 quarters · filed 2015-11-12 | $1.27M 10-Q · filed 2015-11-12 | $1.34M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $1.62M 10-Q · filed 2015-08-13 | $1.68M derived: sum of 3 quarters · filed 2016-03-14 | |
| 2014-03-31 | $589.00K 10-Q · filed 2015-05-13 | $655.00K derived: sum of 2 quarters · filed 2016-03-14 | ||
| 2013-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $177.00K 10-K · filed 2016-03-14 | ||
| 2013-09-30 | $111.00K 10-Q · filed 2014-11-25 | |||
| 2012-12-31 | -$912.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |